The company revealed that it has now signed a Memorandum of Understanding with Attwill Medical Solutions Sterilflow, affirming the parties’ intention to establish AMS as a resource for lyophilization development and large-scale manufacturing, including tablets and enteric coating for Vaxart COVID-19 oral vaccine.
AMS will allocate dedicated resources and equipment for vaccine expansion and commercial production by signing a formal agreement, Vaxart said.
“We believe that AMS experience coupled with its ability to manufacture one billion or more doses per year would be a beneficial addition to our CDMO partner group and would enable the large-scale manufacturing and final supply of our COVID-19 vaccine for EE. The US, Europe and other countries in need, “said Andrei Floroiu, CEO of Vaxart Inc.
He continued: “We believe that our oral vaccines, generated on our proven platform, have the potential to offer superior protection against airborne viruses such as SARS-CoV-2 by activating both systemic and mucosal immunity while administered with a stable tablet at room temperature. , a huge logistical advantage in large vaccination campaigns. “
In fact, Vaxart believes that a stable, room-temperature tablet vaccine is easier to distribute, store, and administer than injectable vaccines, and can provide a significantly faster response to a pandemic than injectable vaccines, allowing protection of more part of the population.
Its development programs include oral tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papilloma virus (HPV).
HC Wainwright analyst Vernon Bernardino has a buy rating and $ 7 price target on Vaxart for this very reason. He believes that an oral route vaccine is a unique and unappreciated differentiator, saying: “While we acknowledge that the Vaxart CoV vaccine development program is at an early stage, we believe that a tabletop oral CoV vaccine could have substantial targeting and delivery benefits. “
The analyst is now looking to start the first Vaxart Phase 1 study with an oral candidate for the CoV vaccine, which he believes will be a positive catalyst in 2H20, especially since the preclinical results were very encouraging. Overall, the stock has a moderate buy analyst consensus. (See VXRT stock analysis at TipRanks).
Latest articles from Smarter Analyst: